Saturday, November 2, 2019

Green Valley Announces NMPA Approval Of Oligomannate For Mild To Moderate Alzheimer's Disease

Oligomannate , A New Oral Treatment For Mild To Moderate Alzheimer's Disease The Only Approved Novel AD Treatment Globally Since 2003 SHANGHAI, Nov. 2, 2019 /PRNewswire/ -- Shanghai Green Valley Pharmaceuticals (Green Valley) today announced that China's National Medical Products...



from PR Newswire: https://ift.tt/2NBkM7P

No comments:

Post a Comment